ERBB2 and breast carcinoma: For this paper, we chose to measure HER2 expression because of its clinical significance, as one-fourth of all breast cancers overexpress HER2, and anti-HER2 targeted therapies substantially lower the risk of recurrence and death for HER2-positive disease11–17.